JS Link, Inc. (KOSDAQ:127120)

Market Cap	1.20T +366.7%
Revenue (ttm)	20.31B +42.3%
Net Income	-15.76B
EPS	-524.37
Shares Out	34.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,774
Open	33,000
Previous Close	31,450
Day's Range	32,300 - 35,350
52-Week Range	8,510 - 49,900
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 84
• Stock Exchange: KOSDAQ
• Ticker Symbol: 127120

Financial Performance

In 2025, JS Link's revenue was 19.32 billion, an increase of 21.43% compared to the previous year's 15.91 billion. Losses were -16.45 billion, 52.2% more than in 2024.